Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/46164
Tipo de documento
PreprintDireito Autoral
Acesso restrito
Data de embargo
2051
Coleções
- INI - Preprint [101]
- IOC - Preprint [149]
Metadata
Mostrar registro completo
ACCURATE DETECTION OF ZIKA VIRUS IGG USING A NOVEL IMMUNE COMPLEX BINDING ELISA
Autor(es)
Ehmen, Christa
Medialdea-Carrera, Raquel
Brown, David
Filippis, Ana Maria Bispo de
Sequeira, Patrícia Carvalho de
Nogueira, Rita Maria Ribeiro
Brasil, Patricia
Calvet, Guilherme Amaral
Blessmann, Jörg
Mallmann, Anna-Maria
Sievertsen, Jürgen
Rackow, Anne
Schmidt-Chanasit, Jonas
Emmerich, Petra
Schmitz, Herbert
Deschermeier, Christina
Mika, Angela
Medialdea-Carrera, Raquel
Brown, David
Filippis, Ana Maria Bispo de
Sequeira, Patrícia Carvalho de
Nogueira, Rita Maria Ribeiro
Brasil, Patricia
Calvet, Guilherme Amaral
Blessmann, Jörg
Mallmann, Anna-Maria
Sievertsen, Jürgen
Rackow, Anne
Schmidt-Chanasit, Jonas
Emmerich, Petra
Schmitz, Herbert
Deschermeier, Christina
Mika, Angela
Afiliação
Bernhard Nocht Institute for Tropical Medicine. Diagnostics Development Laboratory. Hamburg, Germany.
University of Liverpool. Health Protection Research Unit in Emerging and Zoonotic Infections. Liverpool, UK.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência de Flavivírus. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência de Flavivírus. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência de Flavivírus. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência de Flavivírus. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de doenças febris agudas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de doenças febris agudas. Rio de Janeiro, RJ, Brasil.
Bernhard Nocht Institute for Tropical Medicine. Department for Infectious Disease Epidemiology. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Diagnostics Development Laboratory. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Diagnostics Development Laboratory. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Diagnostics Development Laboratory. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Department for Virology. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Department for Virology. Hamburg, Germany / University of Rostock. Center of Internal Medicine II. Department of Tropical Medicine and Infectious Diseases. Rostock, Germany.
Bernhard Nocht Institute for Tropical Medicine. Department for Virology. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Diagnostics Development Laboratory. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Diagnostics Development Laboratory. Hamburg, Germany.
University of Liverpool. Health Protection Research Unit in Emerging and Zoonotic Infections. Liverpool, UK.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência de Flavivírus. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência de Flavivírus. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência de Flavivírus. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência de Flavivírus. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de doenças febris agudas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de doenças febris agudas. Rio de Janeiro, RJ, Brasil.
Bernhard Nocht Institute for Tropical Medicine. Department for Infectious Disease Epidemiology. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Diagnostics Development Laboratory. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Diagnostics Development Laboratory. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Diagnostics Development Laboratory. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Department for Virology. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Department for Virology. Hamburg, Germany / University of Rostock. Center of Internal Medicine II. Department of Tropical Medicine and Infectious Diseases. Rostock, Germany.
Bernhard Nocht Institute for Tropical Medicine. Department for Virology. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Diagnostics Development Laboratory. Hamburg, Germany.
Bernhard Nocht Institute for Tropical Medicine. Diagnostics Development Laboratory. Hamburg, Germany.
Resumo em Inglês
Objectives: Accurate serological assays are urgently needed to support public health responses to Zika virus (ZIKV) infection with its potential to cause foetal damage during pregnancy. Current flavivirus serology for ZIKV infections lacks specificity due to cross-reacting antibodies from closely related other flaviviruses. In this study, we evaluated novel serological tests for accurate ZIKV IgG detection.
Methods: Our ELISAs are based on immune complex binding. The high specificity is achieved by the simultaneous incubation of labelled ZIKV antigen and unlabelled flavivirus homolog protein competitors. Two assays were validated with a panel of 406 human samples from PCR-confirmed ZIKV patients collected in Brazil (n = 154), healthy blood donors and other infections from Brazil, Europe, Canada and Colombia (n = 252).
Results: The highest specificity (100% [252/252, 95% confidence interval (CI) 98.5-100.0]) was shown by the ZIKV ED3 ICB ELISA using the ED3 antigen of the ZIKV envelope. A similar test using the NS1 antigen (ZIKV NS1 ICB ELISA) was slightly less specific (92.1% [232/252, 95% CI 88.0-95.1]). The commercial Euroimmun ZIKV ELISA had a specificity of only 82.1% (207/252, 95% CI 76.8-86.7). Sensitivity was high (93-100%) from day 12 after onset of symptoms in all three tests. Seroprevalence of ZIKV IgG was analysed in 87 samples from Laos (Asia) confirming that the ED3 ELISA showed specific reactions in other populations.
Conclusions: The novel ED3 ICB ELISA will be useful for ZIKV-specific IgG detection for seroepidemiological studies and serological diagnosis for case management in travellers and in countries where other flavivirus infections are co-circulating.
Compartilhar